EGRX News Alert Eagle Pharmaceuticals Inc. (EGRX) 20.98 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 1:29 PM

Eagle Pharmaceuticals Inc. (EGRX) 20.98 $EGRX

Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.76 (-0.14), GILD: 101.90 (+1.10), PSTI: 2.91 (+0.01), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), EGRX: 20.98 (+1.45), BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)

Nasdaq stocks posting largest volume increases
AP - Fri Jan 23, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
EGLE: 9.98 (-0.02), SIBC: 21.10 (+0.22), EGLT: 10.60 (+0.58), GLBZ: 12.65 (+0.35), NERV: 4.68 (+0.09), LPHI: 0.23 (unch), SAL: 28.70 (unch), TGLS: 9.89 (+0.09), EGRX: 20.98 (+1.45), WVFC: 11.02 (-0.45), NATL: 26.86 (-0.11), ATNY: 1.97 (+0.07)

Nasdaq stocks posting largest percentage increases
AP - Fri Jan 23, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
EGLT: 10.60 (+0.58), PFIS: 43.40 (-0.59), EOPN: 8.55 (-0.01), NERV: 4.68 (+0.09), VTAE: 14.40 (+0.82), EGRX: 20.98 (+1.45), CHUY: 22.04 (-0.35), OTIC: 31.14 (+0.13), SNMX: 5.92 (+0.26), INFN: 17.56 (-0.10)

3 Attractive Biotech Picks For 2015
Bret Jensen - at Seeking Alpha - Fri Jan 23, 8:44AM CST

CRIS: 3.23 (+0.25), GILD: 101.90 (+1.10), EGRX: 20.98 (+1.45)

Eagle Pharmaceuticals, Inc. Announces Change in Fiscal Year End
Business Wire - Tue Jan 20, 8:20AM CST
The Board of Directors of Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"

(Nasdaq: EGRX) has approved a change in the Company's fiscal year end to December 31. The change will result in a stub period from October 1, 2014 to December 31, 2014, and as a result of the change, the fiscal year 2015 will end on December 31, 2015. This change in year end from September 30 to December 31 is being made by the Company to better align Eagle's reporting calendar with its industry peers.
EGRX: 20.98 (+1.45)

Eagle Pharmaceuticals (EGRX) Falls: Stock Goes Down 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 7:48AM CST
Make sure to keep an eye on Eagle Pharmaceuticals going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
EGRX: 20.98 (+1.45)

Eagle Pharmaceuitcals: The Next Best Generics Take-Out Story
AvetCap - Seeking Alpha - Mon Dec 22, 6:00AM CST
Eagle is a sub $200m specialty generics company with very little wall street research coverage and fairly small institutional ownership. The stock doesn't trade a lot either. Part of the reason is that some elements of the EGRX story are technical...
EGRX: 20.98 (+1.45)

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Dec 17, 10:51AM CST

EGRX: 20.98 (+1.45)

Eagle Pharma ups revenues 39% in FY14 results
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 6:57AM CST

EGRX: 20.98 (+1.45)

Eagle Pharmaceuticals reports 4Q loss
Automated Insights - Wed Dec 17, 6:48AM CST
WOODCLIFF LAKE, N.J. (AP) _ Eagle Pharmaceuticals Inc. (EGRX) on Wednesday reported a loss of $9.1 million, or 65 cents per share, in its fiscal fourth quarter.
EGRX: 20.98 (+1.45)

Eagle Pharmaceuticals misses by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 6:43AM CST

EGRX: 20.98 (+1.45)

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Year End 2014 Financial Results
Business Wire - Wed Dec 17, 6:38AM CST
Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company"

(Nasdaq: EGRX) today announced its financial results for the three- and twelve- month periods ended September 30, 2014. Highlights of and subsequent to the fourth quarter include:
EGRX: 20.98 (+1.45)

Notable earnings before Wednesday's open
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 4:30PM CST

JOY: 44.14 (+0.35), FDX: 176.47 (+0.17), EGRX: 20.98 (+1.45), GIS: 52.48 (-0.45)

Eagle Pharma reports December 17
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:02AM CST

EGRX: 20.98 (+1.45)

Eagle Pharmaceuticals to Discuss 2014 Fourth Quarter and Year-End Financial Results on December 17, 2014
Business Wire - Thu Dec 04, 4:56PM CST
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company"

announced today that it will release its 2014 fourth quarter and year-end financial results on Wednesday, December 17, 2014, before the market opens.
EGRX: 20.98 (+1.45)

Eagle Pharmaceuticals to Present at Piper Jaffray 2014 Healthcare Conference
Business Wire - Thu Nov 20, 9:00AM CST
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company"

announced today that Scott Tarriff, President and Chief Executive Officer, and David Riggs, Chief Financial Officer, will present at the Piper Jaffray 26th Annual Healthcare Conference as follows:
EGRX: 20.98 (+1.45)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 16, 4:30PM CST

TSN: 40.70 (-0.09), JD: 26.23 (-0.27), EGRX: 20.98 (+1.45), CMGE: 16.13 (+0.37), HGR: 22.98 (+0.15)

Eagle Pharmaceuticals (EGRX) Jumps: Stock Gains 8.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:46AM CST
Eagle Pharmaceuticals (EGRX) was a big mover last session, with shares rising over 8% on the day.
ICUI: 88.98 (+0.42), ABAX: 60.93 (+0.65), GWPH: 78.09 (+1.70), EGRX: 20.98 (+1.45)

Eagle Pharma rapidly infused admix equivalent to Treanda
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 8:51AM CST

EGRX: 20.98 (+1.45)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Skiptown Expands in Georgia Amid Growing Demand

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Quark Baby's Milk Warmer Debut at Vancouver & Dubai

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...